{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:04:00Z","timestamp":1794891840620,"version":"4.9.1"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1186\/s13052-018-0562-1","type":"journal-article","created":{"date-parts":[[2018,11,14]],"date-time":"2018-11-14T08:08:24Z","timestamp":1542182904000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":195,"title":["Enzyme replacement therapy: efficacy and limitations"],"prefix":"10.1186","volume":"44","author":[{"given":"Daniela","family":"Concolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Deodato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Parini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,16]]},"reference":[{"key":"562_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10545-017-0032-8","volume":"40","author":"M Ries","year":"2017","unstructured":"Ries M. Enzyme replacement therapy and beyond\u2014in memoriam roscoe O. Brady, M.D. (1923\u20132016). J Inherit Metab Dis. 2017;40:343\u201356.","journal-title":"J Inherit Metab Dis"},{"key":"562_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/B978-0-12-152826-3.50010-3","volume":"26","author":"WS Sly","year":"1985","unstructured":"Sly WS. Receptor-mediated transport of acid hydrolases to lysosomes. Curr Top Cell Regul. 1985;26:27\u201338.","journal-title":"Curr Top Cell Regul"},{"key":"562_CR3","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","volume":"87","author":"NW Barton","year":"1990","unstructured":"Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Nat AcadSci U S A. 1990;87:1913\u20136.","journal-title":"Proc Nat AcadSci U S A"},{"key":"562_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ymgme.2014.10.017","volume":"114","author":"JE Fox","year":"2015","unstructured":"Fox JE, Volpe L, Bullaro J, Kakkis ED, Sly WS. First human treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab. 2015;114:203\u20138.","journal-title":"Mol Genet Metab"},{"key":"562_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1136\/jmedgenet-2015-103322","volume":"53","author":"AM Monta\u00f1o","year":"2016","unstructured":"Monta\u00f1o AM, Lock-Hock N, Steiner RD, Graham BH, Szlago M, Greenstein R, et al. Clinical course of sly syndrome (mucopolysaccharidosis type VII). J Med Genet. 2016;53:403\u201318.","journal-title":"J Med Genet"},{"issue":"Suppl 5","key":"562_CR6","doi-asserted-by":"publisher","first-page":"v49","DOI":"10.1093\/rheumatology\/ker396","volume":"50","author":"V Valayannopoulos","year":"2011","unstructured":"Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(Suppl 5):v49\u201359.","journal-title":"Rheumatology (Oxford)"},{"key":"562_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1006\/bmme.1996.0044","volume":"58","author":"ED Kakkis","year":"1996","unstructured":"Kakkis ED, McEntee MF, Schmidtchen A, Neufeld EF, Ward DA, Gompf RE, et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. BiochemMol Med. 1996;58:156\u201367.","journal-title":"BiochemMol Med"},{"key":"562_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1006\/mgme.2000.2979","volume":"69","author":"CT Turner","year":"2000","unstructured":"Turner CT, Hopwood JJ, Brooks DA. Enzyme replacement therapy in mucopolysaccharidosis I: altered distribution and targeting of alpha-L-iduronidase in immunized rats. Mol Genet Metab. 2000;69:277\u201385.","journal-title":"Mol Genet Metab"},{"key":"562_CR9","doi-asserted-by":"publisher","first-page":"12937","DOI":"10.1073\/pnas.91.26.12937","volume":"91","author":"RM Shull","year":"1994","unstructured":"Shull RM, Kakkis ED, McEntee MF, Kania SA, Jonas AJ, Neufeld EF. Enzyme replacement in a canine model of hurler syndrome. Proc Natl Acad Sci U S A. 1994;91:12937\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"Suppl 91","key":"562_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/j.1651-2227.2002.tb03115.x","volume":"439","author":"WS Sly","year":"2002","unstructured":"Sly WS. Enzyme replacement therapy: from concept to clinical practice. Acta Paediatr. 2002;439(Suppl 91):71\u20138.","journal-title":"Acta Paediatr"},{"key":"562_CR11","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/156652311794940791","volume":"11","author":"DS Anson","year":"2011","unstructured":"Anson DS, McIntyre C, Byers S. Therapies for neurological disease in the mucopolysaccharidoses. Curr Gene Ther. 2011;11:132\u201343.","journal-title":"Curr Gene Ther"},{"key":"562_CR12","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1542\/peds.2007-3847","volume":"123","author":"LA Clarke","year":"2009","unstructured":"Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics. 2009;123:229\u201340.","journal-title":"Pediatrics"},{"key":"562_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1824-7288-39-53","volume":"39","author":"F Ceravolo","year":"2013","unstructured":"Ceravolo F, Mascaro I, Sestito S, Pascale E, Lauricella A, Dizione E, et al. Home treatment in paediatric patients with Hunter syndrome: the first Italian experience. Ital J Pediatr. 2013;39:53.","journal-title":"Ital J Pediatr"},{"key":"562_CR14","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1007\/s10545-007-0686-8","volume":"30","author":"J Cox-Brinkman","year":"2007","unstructured":"Cox-Brinkman J, Timmermans RG, Wijburg FA, Donker WE, van der Ploeg AT, Aerts JM, et al. Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe. J Inherit Metab Dis. 2007;30:984.","journal-title":"J Inherit Metab Dis"},{"key":"562_CR15","doi-asserted-by":"publisher","unstructured":"Galimberti C, Madeo A, Di Rocco M, Fiumara A. Mucopolysaccharidoses: early diagnostic signs in infants and children. Ital J Pediatr. 2018; https:\/\/doi.org\/10.1186\/s13052-018-0550-5 .","DOI":"10.1186\/s13052-018-0550-5"},{"key":"562_CR16","doi-asserted-by":"publisher","unstructured":"Rigoldi M, Verrecchia E, Manna R, Mascia MT. Clinical hints to diagnosis of attenuated forms of mucopolysaccharidosis. Ital J Pediatr. 2018; https:\/\/doi.org\/10.1186\/s13052-018-0551-4 .","DOI":"10.1186\/s13052-018-0551-4"},{"key":"562_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","volume":"90","author":"M Sifuentes","year":"2007","unstructured":"Sifuentes M, Doroshow R, Hoft R, Mason G, Walot I, Diament M, et al. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol Genet Metab. 2007;90:171\u201380.","journal-title":"Mol Genet Metab"},{"key":"562_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","volume":"13","author":"J Muenzer","year":"2011","unstructured":"Muenzer J, Beck M, Eng CM, Giugliani R, Harmatz P, Martin R, et al. Long term, open-labeled extension study of idursulfase in the treatment of hunter syndrome. Genet Med. 2011;13:95\u2013101.","journal-title":"Genet Med"},{"key":"562_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s10545-014-9686-7","volume":"37","author":"C Lampe","year":"2014","unstructured":"Lampe C, Bosserhoff AK, Burton BK, Giugliani R, de Souza CF, Bittar C, et al. Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case series. J Inherit Metab Dis. 2014;37:823\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"562_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ymgmr.2015.03.011","volume":"3","author":"R Parini","year":"2015","unstructured":"Parini R, Rigoldi M, Tedesco L, Boffi L, Brambilla A, Bertoletti S, et al. Enzymatic replacement therapy for hunter disease: up to 9 years experience with 17 patients. Mol Genet Metab Rep. 2015;3:65\u201374.","journal-title":"Mol Genet Metab Rep"},{"key":"562_CR21","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1002\/ajmg.a.36584","volume":"164A","author":"R Giugliani","year":"2014","unstructured":"Giugliani R, Lampe C, Guffon N, Ketteridge D, Le\u00e3o-Teles E, Wraith JE, et al. Natural history and galsulfase treatment in mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)\u2014ten year follow-up of patients who previously participated in an MPS VI survey study. Am J Med Genet A. 2014;164A:1953\u201364.","journal-title":"Am J Med Genet A"},{"key":"562_CR22","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s10545-014-9715-6","volume":"37","author":"CJ Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Burton B, Fleming TR, Harmatz P, Hughes D, Jones SA, et al. Efficacy and safety of enzyme replacement therapy with BMN 110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomized placebo-controlled study. J Inherit Metab Dis. 2014;37:979\u201390.","journal-title":"J Inherit Metab Dis"},{"issue":"11","key":"562_CR23","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1002\/ajmg.a.38459","volume":"173","author":"M K\u0131l\u0131\u00e7","year":"2017","unstructured":"K\u0131l\u0131\u00e7 M, Dursun A, Co\u015fkun T, Tokatl\u0131 A, \u00d6zg\u00fcl RK, Y\u00fccel-Y\u0131lmaz D, et al. Genotypic-phenotypic features and enzyme replacement therapy outcome in patients with mucopolysaccharidosis VI from Turkey. Am J Med Genet A. 2017;173(11):2954\u201367.","journal-title":"Am J Med Genet A"},{"key":"562_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1006\/mgme.2000.3140","volume":"72","author":"ED Kakkis","year":"2001","unstructured":"Kakkis ED, Schuchman E, He X, Wan Q, Kania S, Wiemelt S, et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab. 2001;72:199\u2013208.","journal-title":"Mol Genet Metab"},{"key":"562_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ymgme.2013.04.002","volume":"110","author":"CJ Hendriksz","year":"2013","unstructured":"Hendriksz CJ, Harmatz P, Beck M, Jones S, Wood T, Lachman R, et al. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Mol Genet Metab. 2013;110:54\u201364.","journal-title":"Mol Genet Metab"},{"key":"562_CR26","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ymgme.2013.02.013","volume":"9","author":"MMG Brands","year":"2013","unstructured":"Brands MMG, Oussoren E, Ruijter GJG, Vollebregt AAM, van den Hout HMP, Joosten KFM, et al. Up to five years experience with 11 mucopolysaccharidosis type VI patients. Mol Genet Metab. 2013;9:70\u20136.","journal-title":"Mol Genet Metab"},{"key":"562_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ymgme.2009.08.006","volume":"99","author":"T Okuyama","year":"2010","unstructured":"Okuyama T, Tanaka A, Suzuki Y, Ida H, Tanaka T, Cox GF, et al. Japan Elaprase treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated hunter syndrome (mucopolysaccharidosis II, MPS II). Mol Genet Metab. 2010;99:18\u201325.","journal-title":"Mol Genet Metab"},{"key":"562_CR28","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10545-010-9059-9","volume":"33","author":"A Tylki-Szymanska","year":"2010","unstructured":"Tylki-Szymanska A, Marucha J, Jurecka A, Syczewska M, Czartoryska B. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis. 2010;33:151\u20137.","journal-title":"J Inherit Metab Dis"},{"key":"562_CR29","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgmr.2016.04.003","volume":"7","author":"HY Lin","year":"2016","unstructured":"Lin HY, Chuang CK, Wang CH, Chien YH, Wang YM, Tsai FJ, et al. Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: a case series. Mol Genet Metab Rep. 2016;7:63\u20139.","journal-title":"Mol Genet Metab Rep"},{"key":"562_CR30","doi-asserted-by":"publisher","unstructured":"Boffi L, Russo P, Limongelli G. Early diagnosis and management of cardiac manifestations in mucopolysaccharidoses: a practical guide for paediatric and adult cardiologists. Ital J Pediatr. 2018; https:\/\/doi.org\/10.1186\/s13052-018-0560-3 .","DOI":"10.1186\/s13052-018-0560-3"},{"key":"562_CR31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3233\/PRM-2012-0194","volume":"5","author":"NR Guarany","year":"2012","unstructured":"Guarany NR, Schwartz IV, Guarany FC, Giugliani R. Functional capacity evaluation of patients with mucopolysaccharidosis. J Pediatr Rehabil Med. 2012;5:37\u201346.","journal-title":"J Pediatr Rehabil Med"},{"key":"562_CR32","first-page":"3421","volume-title":"The metabolic bases of inherited disease","author":"EF Neufeld","year":"2001","unstructured":"Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Blaudet AL, Sly WS, Valle D, editors. The metabolic bases of inherited disease. 8th ed. New York: McGraw Hill; 2001. p. 3421\u201352.","edition":"8"},{"key":"562_CR33","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1517\/14656566.6.3.489","volume":"6","author":"JE Wraith","year":"2005","unstructured":"Wraith JE. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother. 2005;6:489\u2013506.","journal-title":"Expert Opin Pharmacother"},{"key":"562_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s10545-007-0555-5","volume":"30","author":"F Santamaria","year":"2007","unstructured":"Santamaria F, Andreucci MV, Parenti G, Polverino M, Viggiano D, Montella S, et al. Upper airway obstructive disease in mucopolysaccharidoses: polysomnography, computed tomography and nasal endoscopy findings. J Inherit Metab Dis. 2007;30:743\u20139.","journal-title":"J Inherit Metab Dis"},{"key":"562_CR35","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10545-012-9555-1","volume":"36","author":"KI Berger","year":"2013","unstructured":"Berger KI, Fagondes SC, Giugliani R, Hardy KA, Lee KS, McArdle C, et al. Respiratory and sleep disorders in mucopolysaccharidosis. J Inherit Metab Dis. 2013;36:201\u201310.","journal-title":"J Inherit Metab Dis"},{"key":"562_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13023-015-0255-4","volume":"10","author":"AR Pal","year":"2015","unstructured":"Pal AR, Langereis EJ, Saif MA, Mercer J, Church HJ, Tylee KL, et al. Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Orphanet J Rare Dis. 2015;10:42.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"562_CR37","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.bjorl.2015.09.006","volume":"82","author":"Ana Paula Fiuza Funicello Dualibi","year":"2016","unstructured":"Dualibi AP, Martins AM, Moreira GA, de Azevedo MF, Fujita RR, Pignatari SS. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis. Braz J Otorhinolaryngol 2016;82:522\u2013528.","journal-title":"Brazilian Journal of Otorhinolaryngology"},{"key":"562_CR38","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00431-011-1606-3","volume":"171","author":"J Muenzer","year":"2012","unstructured":"Muenzer J, Bodamer O, Burton B, Clarke L, Schulze-Frenking G, Giugliani R, et al. The role of enzyme replacement therapy in severe hunter syndrome\u2014an expert panel consensus. Eur J Pediatr. 2012;171:181\u20138.","journal-title":"Eur J Pediatr"},{"key":"562_CR39","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13023-014-0129-1","volume":"9","author":"R Tomanin","year":"2014","unstructured":"Tomanin R, Zanetti A, D\u2019Avanzo F, Rampazzo A, Gasparotto N, Parini R, et al. Clinical efficacy of enzyme replacement therapy in paediatric hunter patients, an independent study of 3.5 years. Orphanet J Rare Dis. 2014;9:129.","journal-title":"Orphanet J Rare Dis"},{"key":"562_CR40","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ymgme.2013.02.014","volume":"109","author":"DD Horovitz","year":"2013","unstructured":"Horovitz DD, Magalh\u00e3es TS, Acosta A, Ribeiro EM, Giuliani LR, Palhares DB, et al. Enzyme replacement therapy with galsulfase in 34 children younger than five years of age with MPS VI. Mol Genet Metab. 2013;109:62\u20139.","journal-title":"Mol Genet Metab"},{"key":"562_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","volume":"144","author":"JE Wraith","year":"2004","unstructured":"Wraith JE, Clarke L, Beck M, Kolodny EH, Pastores GM, Muenzer J, et al. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human a-l-iduronidase (laronidase). J Pediatr. 2004;144:581\u20138.","journal-title":"J Pediatr"},{"key":"562_CR42","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","volume":"8","author":"J Muenzer","year":"2006","unstructured":"Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng C, et al. A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (hunter syndrome). Genet Med. 2006;8:465\u201373.","journal-title":"Genet Med"},{"key":"562_CR43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3233\/PRM-2010-0100","volume":"3","author":"M Beck","year":"2010","unstructured":"Beck M, Muenzer J, Scarpa M. Evaluation of disease severity in mucopolysaccharidoses. J Pediatr Rehabil Med. 2010;3:39\u201346.","journal-title":"J Pediatr Rehabil Med"},{"key":"562_CR44","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10545-009-9007-8","volume":"33","author":"P Harmatz","year":"2010","unstructured":"Harmatz P, Yu ZF, Giugliani R, Schwartz IV, Guffon N, Teles EL, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: evaluation of long-term pulmonary function in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Inherit Metab Dis. 2010;33:51\u201360.","journal-title":"J Inherit Metab Dis"},{"key":"562_CR45","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s10545-016-9973-6","volume":"39","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ, Berger KI, Parini R, AlSayed MD, Raiman J, Giugliani R, et al. Impact of long-term elosulfase alfa treatment on respiratory function in patients with Morquio A syndrome. J Inherit Metab Dis. 2016;39:839\u201347.","journal-title":"J Inherit Metab Dis"},{"key":"562_CR46","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ymgme.2016.11.007","volume":"120","author":"S Khan","year":"2017","unstructured":"Khan S, Alm\u00e9ciga-D\u00edaz CJ, Sawamoto K, Mackenzie WG, Theroux MC, Pizarro C, et al. Mucopolysaccharidosis IVA and glycosaminoglycans. Mol Genet Metab. 2017;120:78\u201395.","journal-title":"Mol Genet Metab"},{"key":"562_CR47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13023-016-0425-z","volume":"11","author":"M Rutten","year":"2016","unstructured":"Rutten M, Ciet P, van den Biggelaar R, Oussoren E, Langendonk JG, van der Ploegand AT, et al. Severe tracheal and bronchial collapse in adults with type II mucopolysaccharidosis. Orphanet J Rare Dis. 2016;11:50.","journal-title":"Orphanet J Rare Dis"},{"key":"562_CR48","first-page":"33","volume":"33","author":"C Kampmann","year":"2017","unstructured":"Kampmann C, Wiethoff CM, Huth RG, Staatz G, Mengel E, Beck M, et al. Management of life-threatening tracheal stenosis and tracheomalacia in patients with mucopolysaccharidoses. J Inherit Metab Dis Rep. 2017;33:33\u20139.","journal-title":"J Inherit Metab Dis Rep"},{"key":"562_CR49","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","volume":"144","author":"P Harmatz","year":"2004","unstructured":"Harmatz P, Whitley CB, Waber L, Pais R, Steiner R, Plecko B, et al. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J Pediatr. 2004;144:574\u201380.","journal-title":"J Pediatr"},{"key":"562_CR50","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4187\/respcare.03480783","volume":"48","author":"PL Enright","year":"2003","unstructured":"Enright PL. The six-minute walk test. Respir Care. 2003;48:783\u20135.","journal-title":"Respir Care"},{"key":"562_CR51","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","volume":"148","author":"P Harmatz","year":"2006","unstructured":"Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, S\u00e1 Miranda MC, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533\u20139.","journal-title":"J Pediatr"},{"key":"562_CR52","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1016\/j.joca.2013.08.001","volume":"21","author":"V Opoka-Winiarska","year":"2013","unstructured":"Opoka-Winiarska V, Jurecka A, Emeryky A, Tylki-Szymanska A. Osteoimmunology in mucopolysaccharidoses type I, II, VI and VII. Immunological regulation of the osteoarticular system in the course of metabolic inflammation. Osteoarthr Cartil. 2013;21:1813\u201323.","journal-title":"Osteoarthr Cartil"},{"key":"562_CR53","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1542\/peds.2006-2156","volume":"120","author":"JE Wraith","year":"2007","unstructured":"Wraith JE, Beck M, Lane R, van der Ploeg A, Shapiro E, Xue Y, et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics. 2007;120:e37\u201346.","journal-title":"Pediatrics"},{"key":"562_CR54","doi-asserted-by":"publisher","first-page":"589e604","DOI":"10.1590\/S1415-47572010005000093","volume":"33","author":"R Giugliani","year":"2010","unstructured":"Giugliani R, Federhen A, Rojas MV, Vieira T, Artigalas O, Pinto LL, et al. Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment. Genet Mol Biol. 2010;33:589e604.","journal-title":"Genet Mol Biol"},{"key":"562_CR55","first-page":"443e9","volume":"52","author":"P Harmatz","year":"2010","unstructured":"Harmatz P. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures. Turkish J Pediatr. 2010;52:443e9.","journal-title":"Turkish J Pediatr"},{"key":"562_CR56","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","volume":"109","author":"S Laraway","year":"2013","unstructured":"Laraway S, Breen C, Mercer J, Jones S, Wraith EJ. Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings. Mol Genet Metab. 2013;109:315\u20136.","journal-title":"Mol Genet Metab"},{"key":"562_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13023-015-0344-4","volume":"10","author":"NA Al-Sannaa","year":"2015","unstructured":"Al-Sannaa NA, Bay L, Barbouth DS, Benhayoun Y, Goizet C, Guelbert N, et al. Early treatment with laronidase improves clinical outcomes in patients with attenuated MPS I: a retrospective case series analysis of nine sibships. Orphanet J Rare Dis. 2015;10:131.","journal-title":"Orphanet J Rare Dis"},{"key":"562_CR58","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ymgme.2012.12.010","volume":"108","author":"G Tajima","year":"2013","unstructured":"Tajima G, Sakura N, Kosuga M, Okuyama T, Kobayashi M. Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings. Mol Genet Metab. 2013;108:172\u20137.","journal-title":"Mol Genet Metab"},{"key":"562_CR59","doi-asserted-by":"publisher","first-page":"e183","DOI":"10.1542\/peds.2009-1728","volume":"125","author":"O Gabrielli","year":"2010","unstructured":"Gabrielli O, Clarke LA, Bruni S, Coppa GV. Enzyme-replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I: 5-year follow-up. Pediatrics. 2010;125:e183\u20137.","journal-title":"Pediatrics"},{"key":"562_CR60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12881-016-0284-4","volume":"17","author":"O Gabrielli","year":"2016","unstructured":"Gabrielli O, Clarke LA, Ficcadenti A, Santoro L, Zampini L, Volpi N, et al. 12 year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment. BMC Med Genet. 2016;17:19.","journal-title":"BMC Med Genet"},{"key":"562_CR61","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1111\/j.1651-2227.2011.02385.x","volume":"101","author":"A Tylki-Szymanska","year":"2012","unstructured":"Tylki-Szymanska A, Jurecka A, Zuber Z, Rozdzynska A, Marucha J, Czartoryska B. Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr. 2012;101:e42\u20137.","journal-title":"Acta Paediatr"},{"key":"562_CR62","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1399-0004.2009.01324.x","volume":"77","author":"JJ McGill","year":"2010","unstructured":"McGill JJ, Inwood AC, Coman DJ, Lipke ML, de Lore D, Swiedler SJ, et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age\u2014a sibling control study. Clin Genet. 2010;77:492\u20138.","journal-title":"Clin Genet"},{"key":"562_CR63","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/pr.2015.169","volume":"78","author":"SA Jones","year":"2015","unstructured":"Jones SA, Bialer M, Parini R, Martin K, Wang H, Yang K, et al. Safety and clinical activity of elosulfase alfa in pediatric patients with Morquio A syndrome (mucopolysaccharidosis IVA) less than 5 y. Pediatr Res. 2015;78:717\u201322.","journal-title":"Pediatr Res"},{"key":"562_CR64","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.ymgme.2013.11.015","volume":"111","author":"J Muenzer","year":"2014","unstructured":"Muenzer J. Early initiation of enzyme replacement therapy for the mucopolysaccharidoses. Mol Genet Metab. 2014;111:63\u201372.","journal-title":"Mol Genet Metab"},{"key":"562_CR65","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1442-9071.2010.02364.x","volume":"28","author":"JL Ashworth","year":"2010","unstructured":"Ashworth JL, Kruse FE, Bachmann B, Tormene AP, Suppiej A, Parini R, et al. Ocular manifestations in the mucopolysaccharidoses\u2014a review. Clin Exp Ophthalmol. 2010;28:12\u201322.","journal-title":"Clin Exp Ophthalmol"},{"key":"562_CR66","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1001\/archopht.125.10.1353","volume":"125","author":"S Pitz","year":"2007","unstructured":"Pitz S, Ogun O, Bajbouj M, Arash L, Schulze-Frenking G, Beck M. Ocular changes in patients with mucopolysaccharidosis I receiving enzyme replacement therapy: a 4-year experience. Arch Ophthalmol. 2007;125:1353\u20136.","journal-title":"Arch Ophthalmol"},{"key":"562_CR67","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00417-008-1030-1","volume":"247","author":"S Pitz","year":"2009","unstructured":"Pitz S, Ogun O, Arash L, Miebach E, Beck M. Does enzyme replacement therapy influence the ocular changes in type VI mucopolysaccharidosis? Graefes Arch Clin Exp Ophthalmol. 2009;247:975\u201380.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"562_CR68","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2147\/OPTH.S78368","volume":"9","author":"CR Fenzl","year":"2015","unstructured":"Fenzl CR, Teramoto K, Moshirfar M. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol. 2015;9:1633\u201344.","journal-title":"Clin Ophthalmol"},{"key":"562_CR69","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1755-3768.2011.02280.x","volume":"90","author":"KT Fahnehjelm","year":"2012","unstructured":"Fahnehjelm KT, Ashworth JL, Pitz S, Olsson M, T\u00f6rnquist AL, Lindahl P, et al. Clinical guidelines for diagnosing and managing ocular manifestations in children with mucopolysaccharidosis. Acta Ophthalmol. 2012;90:595\u2013602.","journal-title":"Acta Ophthalmol"},{"key":"562_CR70","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jpeds.2016.08.033","volume":"178","author":"S Laraway","year":"2016","unstructured":"Laraway S, Mercer J, Jameson E, Ashworth J, Hensman P, Jones SA. Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I. J Pediatr. 2016;178:219\u201326.","journal-title":"J Pediatr"},{"key":"562_CR71","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761\u20139.","journal-title":"Arthritis Rheum"},{"key":"562_CR72","doi-asserted-by":"publisher","first-page":"S51","DOI":"10.1016\/j.ymgme.2014.12.104","volume":"114","author":"P Harmatz","year":"2015","unstructured":"Harmatz P, Treadwell M, Burton BK, Mitchell J, Muschol N, Jones S, et al. Impact of elosulfase alfa on pain in patients with Morquio syndrome type A. Mol Genet Metab. 2015;114:S51\u20132.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"562_CR73","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ymgme.2014.08.012","volume":"114","author":"Christian J. Hendriksz","year":"2015","unstructured":"Hendriksz CJ, Giugliani R, Harmatz P, Mengel E, Guffon N, Valayannopoulos V, et al. Multi-domain impact of elosufase alfa in Morquio syndrome in the pivotal phase III trial. Mol Genet Metab 2015;114:178\u2013185.","journal-title":"Molecular Genetics and Metabolism"},{"issue":"1","key":"562_CR74","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1750-1172-9-32","volume":"9","author":"Christian J Hendriksz","year":"2014","unstructured":"Hendriksz CJ, Lavery C, Coker M, Ucar SK, Jain M, Bell L, et al. Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis. 2014;9:32.","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"562_CR75","doi-asserted-by":"publisher","first-page":"e681","DOI":"10.1542\/peds.2004-1023","volume":"115","author":"P Harmatz","year":"2005","unstructured":"Harmatz P, Ketteridge D, Giugliani R, Guffon N, Teles EL, Miranda MC, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681\u20139.","journal-title":"Pediatrics"},{"key":"562_CR76","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1021\/bc400319d","volume":"24","author":"RJ Boado","year":"2013","unstructured":"Boado RJ, Hui EK, Lu JZ, Sumbria RK, Pardridge WM. Blood\u2013brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem. 2013;24:1741\u20139.","journal-title":"Bioconjug Chem"},{"key":"562_CR77","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1750-1172-6-55","volume":"6","author":"MH de Ru","year":"2011","unstructured":"de Ru MH, Boelens JJ, Das AM, Jones SA, van der Lee JH, Mahlaoui N, et al. Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.","journal-title":"Orphanet J Rare Dis"},{"key":"562_CR78","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/bjh.13059","volume":"167","author":"JJ Boelens","year":"2014","unstructured":"Boelens JJ, Orchard PJ, Wynn RF. Transplantation in inborn errors of metabolism: current considerations and future perspectives. Br J Haematol. 2014;167:293\u2013303.","journal-title":"Br J Haematol"},{"key":"562_CR79","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1182\/blood-2014-11-608075","volume":"125","author":"M Aldenhoven","year":"2015","unstructured":"Aldenhoven M, Wynn RF, Orchard PJ, O'Meara A, Veys P, Fischer A, et al. Long-term outcome of hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood. 2015;125:2164\u201372.","journal-title":"Blood"},{"key":"562_CR80","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/ana.24246","volume":"76","author":"MD Poe","year":"2014","unstructured":"Poe MD, Chagnon SL, Escolar ML. Early treatment is associated with improved cognition in hurler syndrome. Ann Neurol. 2014;76:747\u201353.","journal-title":"Ann Neurol"},{"key":"562_CR81","first-page":"S1083","volume":"30551\u20137","author":"F Kubaski","year":"2017","unstructured":"Kubaski F, Yabe H, Suzuki Y, Seto T, Hamazaki T, Mason RW, et al. Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II. Biol Blood Marrow Transplant. 2017;30551\u20137:S1083\u20138791.","journal-title":"Biol Blood Marrow Transplant"},{"key":"562_CR82","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jpeds.2007.10.015","volume":"152","author":"DJ Coman","year":"2008","unstructured":"Coman DJ, Hayes IM, Collins V, Sahhar M, Wraith JE, Delatycki MB. Enzyme replacement therapy for mucopolysaccharidoses: opinions of patients and families. J Pediatr. 2008;152:723\u20137.","journal-title":"J Pediatr"},{"key":"562_CR83","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ymgme.2011.02.018","volume":"103","author":"BK Burton","year":"2011","unstructured":"Burton BK, Whiteman DA, Hunter Outcome Survey Investigators. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab. 2011;103:113\u201320.","journal-title":"Mol Genet Metab"},{"key":"562_CR84","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ymgme.2008.04.001","volume":"94","author":"P Harmatz","year":"2008","unstructured":"Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, Wraith JE, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase. Mol Genet Metab. 2008;94:469\u201375.","journal-title":"Mol Genet Metab"},{"key":"562_CR85","first-page":"571","volume":"21","author":"CD Serrano","year":"2011","unstructured":"Serrano CD, Gomez JF. Successful desensitization to idursulfase in a patient with type II mucopolysaccharidosis (hunter syndrome). J Investig Allergol Clin Immunol. 2011;21:571\u20132.","journal-title":"J Investig Allergol Clin Immunol"},{"key":"562_CR86","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/j.jaip.2017.02.020","volume":"5","author":"H Guvenir","year":"2017","unstructured":"Guvenir H, Dibek Misirlioglu E, Capanoglu M, Buyuktiryaki B, Unal O, Toyran M, Kocabas CN. Successful desensitization of elosulfase alfa-induced anaphylaxis in a pediatric patient with Morquio syndrome. J Allergy Clin Immunol Pract. 2017;5:1156\u20137.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"562_CR87","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.clinthera.2016.11.017","volume":"39","author":"B Long","year":"2017","unstructured":"Long B, Tompkins T, Decker C, Jesaitis L, Khan S, Slasor P, et al. Long-term immunogenicity of elosulfase alfa in the treatment of Morquio A syndrome: results from MOR-005, a phase III extension study. Clin Thera. 2017;39:118\u2013129.e3.","journal-title":"Clin Thera"},{"key":"562_CR88","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/1750-1172-8-51","volume":"8","author":"MM Brands","year":"2013","unstructured":"Brands MM, Hoogeveen-Westerveld M, Kroos MA, Nobel W, Ruijter GJ, \u00d6zkan L, et al. Mucopolysaccharidosis type VI phenotypes-genotypes and antibody response to galsulfase. Orphanet J Rare Dis. 2013;8:51.","journal-title":"Orphanet J Rare Dis"},{"key":"562_CR89","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","volume":"13","author":"SG Banugaria","year":"2011","unstructured":"Banugaria SG, Prater SN, Ng JK, Kobori JA, Finkel RS, Ladda RL, et al. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011;13:729\u201336.","journal-title":"Genet Med"},{"issue":"4","key":"562_CR90","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1681\/ASN.2013030290","volume":"25","author":"H Debiec","year":"2014","unstructured":"Debiec H, Valayannopoulos V, Boyer O, N\u00f6el LH, Callard P, Sarda H, et al. Allo-immune membranous nephropathy and recombinant arylsulfatase replacement therapy: a need for tolerance induction therapy. J Am Soc Nephrol. 2014;25(4):675\u201380.","journal-title":"J Am Soc Nephrol"},{"key":"562_CR91","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.ymgmr.2017.01.004","volume":"10","author":"R Giugliani","year":"2017","unstructured":"Giugliani R, Vieira TA, Carvalho CG, Mu\u00f1oz-Rojas MV, Semyachkina AN, Voinova VY, et al. Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I. Mol Genet Metab Rep. 2017;10:61\u20136.","journal-title":"Mol Genet Metab Rep"},{"key":"562_CR92","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ymgmr.2014.11.007","volume":"2","author":"KH Kim","year":"2015","unstructured":"Kim KH, Messinger YH, Burton BK. Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II. Mol Genet Metab Rep. 2015;2:20\u20134.","journal-title":"Mol Genet Metab Rep"},{"key":"562_CR93","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jpeds.2016.11.036","volume":"182","author":"LA Clarke","year":"2017","unstructured":"Clarke LA, Atherton AM, Burton BK, Day-Salvatore DL, Kaplan P, Leslie ND, Scott CR, et al. Mucopolysaccharidosis type I newborn screening: best practices for diagnosis and management. J Pediatr. 2017;182:363\u201370.","journal-title":"J Pediatr"},{"key":"562_CR94","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ajmg.a.38073","volume":"173","author":"I Nestrasil","year":"2017","unstructured":"Nestrasil I, Shapiro E, Svatkova A, Dickson P, Chen A, Wakumoto A, et al. Intrathecal enzyme replacement therapy reverses cognitive decline in mucopolysaccharidosis type I. Am J Med Genet A. 2017;173:780\u20133.","journal-title":"Am J Med Genet A"},{"key":"562_CR95","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1517\/14728214.2016.1123690","volume":"21","author":"R Giugliani","year":"2016","unstructured":"Giugliani R, Federhen A, Vairo F, Vanzella C, Pasqualim G, da Silva LM, et al. Emerging drugs for the treatment of mucopolysaccharidoses. Expert Opin Emerg Drugs. 2016;21:9\u201326.","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0562-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13052-018-0562-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0562-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:57:08Z","timestamp":1775267828000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-018-0562-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":95,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["562"],"URL":"https:\/\/doi.org\/10.1186\/s13052-018-0562-1","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"16 November 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RP participated as principal investigator in the phase III trial for ERT in MPS IVA (BioMarin) and has recently participated as subinvestigator to the phase I\/II trial for intrathecal ERT in MPS IIIA (Shire). RP has received honoraria for consulting or speaking engagement from BioMarin, Sanofi Genzyme, SOBI, and Shire. DC has received honoraria for speaking engagements from Shire and Sanofi Genzyme. FD has received honoraria for speaking engagements from Sanofi Genzyme and Shire.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"120"}}